32.2 C
Vientiane
Saturday, May 31, 2025
spot_img
Home Blog Page 175

Zepp Health Corporation to Report First Quarter 2025 Financial Results on May 19, 2025

Earnings Call Scheduled for 9:00 p.m. ET on May 19, 2025

MILPITAS, Calif., May 7, 2025 /PRNewswire/ — Zepp Health Corporation (“Zepp Health” or the “Company”) (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it will report its first quarter 2025 unaudited financial results after the market close on Monday, May 19, 2025.

Management will hold a conference call at 9:00 p.m. Eastern Time on Monday, May 19, 2025. Listeners may access the call by dialing:

US (Toll Free):

+1-888-346-8982

International:

+1-412-902-4272

Mainland China (Toll Free):

400-120-1203

Hong Kong (Toll Free):

800-905-945

Hong Kong:

+852-3018-4992

Participants should dial in at least 10 minutes before the scheduled start time and ask to be connected to the call for “Zepp Health Corporation.”

Additionally, a live and archived webcast of the conference call will be available at http://ir.zepp.com.

A telephone replay will be available one hour after the end of the conference until May 26, 2025 by dialing the following telephone numbers:

US (Toll Free):            

+1-877-344-7529

International:

+1-412-317-0088

Replay Passcode:

5798726

 

About Zepp Health Corporation

Zepp Health Corporation (NYSE: ZEPP) is a global smart wearable and health technology leader, empowering users to live their healthiest lives by optimizing their health, fitness, and wellness journeys through its leading consumer brands, Amazfit, Zepp Clarity and Zepp Aura. Powered by its proprietary Zepp Digital Management Platform, which includes the Zepp OS, AI chips, biometric sensors and data algorithms, Zepp delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. To date, Zepp has shipped over 200 million units, and its products are available in more than 90 countries and regions. Founded in 2013 as Huami Corp., the Company changed its name to Zepp Health Corporation in February 2021 to emphasize its health focus with a name that resonates across languages and cultures globally. Zepp has team members and offices across globe, especially in Europe and USA regions.

For more information on Zepp Health and its products, please visit www.zepp.com.

For investor and media inquiries, please contact: 

Zepp Health Corporation
Grace Yujia Zhang
Email: ir@zepp.com 

Piacente Financial Communications
Email: zepp@tpg-ir.com

accesso® Acquires Technology of 1RISK

Leading Online Waiver and Risk Management Data Solutions to Be Offered Exclusively via Expanded  accesso  Ecosystem

TWYFORD, England, May 7, 2025 /PRNewswire/ — accesso Technology Group (AIM: ACSO), the premier technology solutions provider for attractions and venues worldwide, today announced the asset acquisition of 1RISK – a leader in cloud-based online liability waiver and incident risk management data technology for the leisure and recreation industries, with particular strength in the ski sector.

Founded in 2012, 1RISK developed technology to streamline the process of securing liability waivers for activities such as ticket and pass purchases, equipment rentals and lessons. Over the years, the SaaS-based solutions were expanded to include critical risk management tools, such as incident reporting and dispatch operations tracking, allowing operators to leverage data to reduce the frequency and severity of incidents over time.

The 1RISK liability waiver application, 1Waiver, is the market leading solution for ski resorts across North America.  With more than 160 venues across North America – nearly half of which are also accesso clients – the technology enabled the completion of over 4 million waivers in 2024 alone. accesso has long supported integration with 1Waiver across its eCommerce and point-of-sale technologies. Moving forward, the 1RISK range of solutions will be included as part of accesso’s broader suite of offerings and will be made available exclusively to venues utilizing accesso products.

“As the leading provider of commerce solutions for the ski operators across North America, further enhancing the Accesso offering with 1RISK’s proven technology extends our commitment to delivering innovative, comprehensive solutions to the leisure sector,” said Steve Brown, CEO of accesso.

Charles Mickley, founder and CEO of 1RISK, shared: “As a long-standing partner of Accesso, we have seen first-hand their dedication to innovation and guest experience. We are excited to see the range of 1RISK technology become an integral part of Accesso’s powerful ecosystem, helping operators support their overall approach to risk management.”

Following completion of the asset acquisition, staff members from 1RISK will join accesso and continue to support the development of leading-edge risk management technologies tailored for the needs of ski resorts, recreation venues and activity-based destinations worldwide.

About accesso Technology Group plc
accesso is the leading global provider of patented and award-winning technology solutions that redefine the guest experience, drive increased revenue, streamline operations, and support data-driven business decisions for leisure and entertainment operators. Currently serving over 1,200 venues worldwide, accesso invests heavily in research and development to provide venues with technology that empowers unforgettable guest experiences. Staffed by a team of attractions, cultural venue, and ski industry veterans, accesso partners with venues to maximize guest engagement and revenue through intuitive ticketing, point-of-sale, virtual queuing, distribution, and experience management technologies.

accesso is a public company, listed on AIM: a market operated by the London Stock Exchange. Learn more at accesso.com or follow accesso on X (Twitter), LinkedIn and Facebook.

About 1RISK
1RISK technology provides an easy and efficient method of data entry that allows resorts and businesses to track and analyze customer and workplace incidents. The broad range of 1RISK solutions help operators reduce the frequency and severity of incidents while improving operational insights.

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of ‘Merigolix (TU2670/DW4902)’ for Uterine Fibroids

  • Primary Endpoint Met: Statistically significant reduction in heavy menstrual bleeding achieved in all dosage of Merigolix groups compared to placebo
  • Broader Therapeutic Potential: Positive Phase 2 results in both uterine fibroids and endometriosis could place Merigolix as a strong best-in-class candidate for novel drug approval and global licensing opportunities
  • Multi-Indication Development: Clinical trials are underway for three indications enhancing the asset value-uterine fibroids, endometriosis, and assisted reproductive technology (ART), the latter in collaboration with Hansoh Pharma in China

SEONGNAM, South Korea, May 7, 2025 /PRNewswire/ — TiumBio (KRX: 321550.KQ), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare and incurable disease, today announced that Merigolix (code name: TU2670, Daewon’s code name: DW4902) has successfully met the primary endpoint of reducing heavy menstrual bleeding in a Phase 2 clinical trial for uterine fibroids. In this trial, Merigolix demonstrated statistically significant improvements across all dosage groups compared to placebo in patients with uterine fibroids.

Merigolix is an investigational, once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist. Unlike traditional GnRH agonists, which require injection and often lead to an initial hormone surge, Merigolix offers a more patient-friendly oral administration without an initial hormonal flare, providing a faster onset of action and improved treatment adherence.

The Phase 2 clinical trial of Merigolix in uterine fibroids was conducted by TiumBio’s partner, Daewon Pharmaceutical, and enrolled a total of 71 women diagnosed with uterine fibroids. Participants were randomly assigned to receive high, medium, or low doses of Merigolix, or placebo, administered orally once daily for 12 weeks, followed by a 12-week observation period. The results showed that Merigolix led to statistically significant improvements in heavy menstrual bleeding (HMB)—a validated clinical endpoint—across all dosage groups compared to the placebo.

In addition to the primary endpoint, Merigolix demonstrated statistically and clinically meaningful improvements in several key secondary endpoints, including fibroid size reduction, increased hemoglobin levels (indicating improved anemia), and relief of pelvic pain. The safety and tolerability profile of Merigolix was consistent with prior clinical data, with no new safety signs.

The mechanism of action of Merigolix can be used in various disorders, including endometriosis, uterine fibroids, ART, precocious puberty, and prostate cancer. Notably, in a separate Phase 2 clinical trial for endometriosis completed in 2024, Merigolix also showed excellent therapeutic efficacy and safety, further reinforcing its potential as a promising new treatment.

“We are very excited that Merigolix has demonstrated excellent therapeutic efficacy not only in endometriosis but also in uterine fibroids,” said Hun-Taek Kim, Ph.D., MBA, CEO of TiumBio. “successfully achieving both efficacy and safety in Phase 2 significantly increases the probability of regulatory approval and licensing opportunities. We plan to accelerate development and expand into the global uterine fibroid treatment market,” he added.

“Uterine fibroids are a condition that causes significant suffering for many women, and we believe Merigolix has the potential to become an important new oral treatment that addresses this unmet medical need,” said Jonathan In Baek, President of Daewon Pharmaceutical. “We are pleased with the positive results in uterine fibroids and will continue our efforts to provide patients with a convenient and effective new treatment option,” he continued.

Uterine fibroids are benign tumors that develop in the uterus, primarily affecting women of reproductive age, particularly those in their 30s and older. The condition has a high prevalence rate of approximately 20% among women over the age of 35. The most common symptom is heavy menstrual bleeding, but it can also cause abnormal uterine bleeding, pelvic pain, and anemia.

Meanwhile, TiumBio entered into a licensing agreement with Daewon Pharmaceutical in 2019, granting Daewon the rights to develop and commercialize Merigolix in South Korea.

About TiumBio Co., Ltd.

TiumBio (KRX: 321550.KQ) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients with rare and incurable diseases. Its mission is to expand the hope and happiness of mankind through our science. TiumBio has three leading pipeline assets: Merigolix (code name: TU2670), TU2218, and TU7710, all in various stages of clinical development.

Merigolix is a once-daily, oral GnRH receptor antagonist being developed for the treatment of endometriosis, uterine fibroids, and assisted reproductive technology. TU2218 is a first-in-class oral immune-oncology therapy targeting TGF-β and VEGF pathways to promote response rates in cancer patients when used in combination with immune checkpoint inhibitors. TU7710 is a novel rFVIIa designed to extend its half-life in order to provide more clinical benefits to hemophilia patients with inhibitors.

With its expertise in drug development, TiumBio is committed to the discovery and development of innovative treatments to ease the burden of debilitating diseases. For further information, visit our website at www.tiumbio.com/en and connect with us on LinkedIn.

Contacts:

Junseok Jang, Head of Corporate Communications & Investor Relations
junseokjang@tiumbio.com

Da-ye Song, Manager, Corporate Communications & Investor Relations
dayesong@tiumbio.com

Plusgrade and Atlantis Dubai Partner to Enhance Guest Experiences with Seamless Upgrade Solutions

  • Tailored luxury: Guests at Atlantis Dubai’s two resorts – Atlantis, The Palm and Atlantis The Royal – can now access premium room upgrades, stay extensions, and experiences with ease.
  • Seamless integration: Plusgrade’s enterprise upselling platform integrates with Atlantis Dubai’s systems to automate and personalize upsell offers.
  • Proven success: Building on a successful pilot, this partnership sets a new standard for upsell in ultra-luxury hospitality.

MONTREAL, May 7, 2025 /PRNewswire/ — Plusgrade, a global leader in ancillary revenue solutions for the travel industry, is thrilled to announce its partnership with Atlantis Dubai’s two premier luxury resorts: Atlantis, The Palm and Atlantis The Royal. This collaboration introduces an innovative solution that enhances the guest experience by offering seamless access to premium room upgrades, stay extensions, and exclusive experiences, unlocking new revenue opportunities through an intelligent, fully automated, and white-labeled platform.

A Smarter Approach to Personalized Luxury

With this seamless integration, Atlantis Dubai replaces a legacy system with an intuitive, fully automated platform. Now, guests can bid on or purchase upgrades in a way that is effortless, highly personalized, and aligned with the resort’s commitment to world-class hospitality. Beyond premium room upgrades, the platform provides guests with even more opportunities to enhance their stay, offering greater flexibility and choice throughout their journey.

The initiative follows a successful pilot at Atlantis, The Palm, where Plusgrade’s solution increased both guest satisfaction and incremental revenue, reinforcing its value as a strategic hospitality technology partner.

Elevating Every Guest Stay

“The power of bidding technology transforms the way travelers interact with their journey,” said Daniele Carrai, Vice President, Revenue Management, Atlantis Dubai. “Having seen the value of Plusgrade’s solutions during my time in the cruise industry, I am thrilled to bring this level of innovation to Atlantis Dubai. Our ‘innovation partnership’ with Plusgrade allows us to push boundaries and continuously evolve our guest offerings. Their commitment to delivering against our unique needs has made them an invaluable partner as we work together to redefine luxury travel.”

“At Atlantis, our guests expect a level of luxury and personalization that sets new benchmarks in the ultra-luxury market,” said Michael Chatzidakis, Director, Revenue Management, Atlantis Dubai. “The ease of using Plusgrade’s intelligent platform allows us to elevate every aspect of the guest journey, offering tailored services and experiences that make each stay unforgettable.”

Powering the Future of Guest Engagement

“Our partnership with Atlantis Dubai is a perfect example of how technology can enhance the guest experience while driving significant ancillary revenue,” said Ken Harris, Founder and CEO of Plusgrade. “By integrating our intelligent upgrade solution, along with other personalized upsell opportunities, we are giving guests greater choice and flexibility while helping Atlantis Dubai unlock new revenue streams. We are proud to work with these iconic resorts to set a new benchmark for luxury hospitality.”

Key Benefits of the Program

  1. Exclusive Upgrades: Guests can bid on or purchase room upgrades, ensuring a tailored and elevated stay.
  2. Seamless Experience: Fully integrated with Atlantis Dubai’s brand and booking systems for effortless personalization.
  3. Maximized Guest Engagement: A range of upsell opportunities ensures every guest can enhance their stay in a way that suits their needs.

This partnership marks a major step in Atlantis Dubai’s commitment to innovation in hospitality, delivering a more personalized and seamless guest experience. With bidding capabilities now live, guests at Atlantis, The Palm and Atlantis The Royal can instantly access exclusive upgrades and experiences.

About Plusgrade

Plusgrade powers the global travel industry with its portfolio of leading ancillary revenue solutions. Over 250 airline, hospitality, cruise, passenger rail, and financial services companies trust Plusgrade to create new, meaningful revenue streams through incredible customer experiences. As the ancillary revenue powerhouse, Plusgrade has generated billions of dollars in new revenue opportunities across its platform for its partners, while creating enhanced travel experiences for millions of their passengers and guests. Plusgrade was founded in 2009 with headquarters in Montreal and has offices around the world. For more information, visit plusgrade.com.

About Atlantis Dubai

Atlantis Dubai is a world-renowned luxury destination comprised of two iconic resorts, Atlantis, The Palm and Atlantis The Royal, offering unparalleled opulence, adventure, and hospitality. Atlantis, The Palm is the region’s first entertainment resort, home to the world-famous Aquaventure World Waterpark with record-breaking slides, The Lost Chambers Aquarium with over 65,000 marine animals, and a vibrant culinary scene featuring Michelin-starred and celebrity chef restaurants. Atlantis The Royal redefines ultra-luxury with cutting-edge design, offering experiences like sky-high pools, fire-breathing fountains, and the world’s largest collection of celebrity chef restaurants. Recognized as the 9th best resort in the world by The World’s 50 Best Resorts 2024, Atlantis The Royal sets a new benchmark for luxury. From award-winning dining and world-class entertainment to awe-inspiring architecture, Atlantis Dubai is where extraordinary moments come to life.
https://www.atlantis.com/

Media Contact: Carrie Moench, Director, Brand & Communications, Plusgrade, pr@plusgrade.com

Pharos Network Unveils High-Performance Layer 1 Testnet to Unlock RWA Adoption

HONG KONG, May 7, 2025 /PRNewswire/ — Pharos Network, a high-performance blockchain built for real-world assets (RWAs), announced the launch of its Testnet today. Designed for institutional-grade RWAs and enterprise-scale DeFi, Pharos offers a next-generation, modular infrastructure that addresses the key bottlenecks preventing institutions from entering Web3. The platform powers scalable deployment of decentralized applications, enables efficient payment solutions, and unlocks new use cases for tokenized assets.

The Pharos Testnet achieves up to 30,000 transactions per second with one-second finality, setting a new benchmark for Layer 1 blockchain performance. Its GPU-like architecture could support billions of users and reduce storage usage by 80%. The network also features built-in support for decentralized AI and privacy preserving SPN. With ZK-based KYC/AML capabilities, Pharos ensures enterprise-ready security and compliance. It remains fully EVM-compatible, offering faster and cheaper transactions, while enabling flexible, on-chain innovation.

Pharos’s product stack directly addresses the core bottlenecks in RWA adoption—scalability, compliance, and flexibility—unlocking new use cases across sectors such as renewable energy industry finance, payment, supply chain finance, and tokenized real estate. Its modular, high-throughput infrastructure enables secure deployment of RWA at scale, while meeting the regulatory and performance demands of the financial industry.

A growing ecosystem is already emerging on the Pharos Testnet, enabling innovative Defi use cases for RWAs. As an early collaborator of Pharos, OKX Wallet will support Pharos Testnet natively at launch. Early Pharos ecosystem projects include Zenith Swap, ELFi, Buzzing Club, Nextmate.AI, Faroswap, R2, OpenFi, Hemera, Blocksense, Supra, and more.

Founded by former AntChain and Alibaba blockchain leaders, the Pharos team brings deep enterprise experience, uniquely positioning it to deliver enterprise-grade solutions for institutions exploring green finance, payments, and new forms of programmable ownership and asset tokenization.

“The Pharos Testnet represents a significant milestone in our mission to unlock the true potential of RWAs. By providing a high-performance, scalable, and adaptable platform, Pharos meet the needs of bringing real world assets on a chain and bringing utilities to these assets.” said Alex Zhang, CEO of Pharos Network. “We’re excited to watch innovation flourish on Pharos and accelerate the convergence of traditional finance and decentralized technology.

Developers and users can access and experience the Testnet by visiting testnet.pharosnetwork.xyz.

About Pharos

Pharos Network is a revolutionary Layer 1 blockchain platform that sets new benchmarks in decentralized technology with its extreme performance and scalability. Founded by ex-blockchain leaders from Ant Financial and Alibaba, Pharos aims to build the best chain for RWAs and enterprise-grade DeFi, achieving the highest EVM Layer-1 performance with 50K TPS and being the first to reach 2 gigagas/sec. In addition, Pharos is a co-developer of SmartCogent, an AI toolkit for large language models (LLMs), and the core development team of DTVM technology. For more information, please visit https://pharosnetwork.xyz.

THE WORLD’S MOST FAMOUS AND PAMPERED FELINE CHOUPETTE STARS IN HUBLOT’S BIG BANG 20TH ANNIVERSARY CAMPAIGN

NYON, Switzerland, May 7, 2025 /PRNewswire/ — The internet’s reigning feline icon, Choupette, has landed her most unexpected role with luxury’s most polarizing watch brand Hublot. The Swiss watchmaker has tapped fashion’s famously pampered cat to celebrate its 20th anniversary of the iconic Big Bang collection.

Hublot Big Bang 20th Anniversary campaign with Choupette
Hublot Big Bang 20th Anniversary campaign with Choupette

Known for rewriting the rules of luxury, Hublot is the antithesis of quiet design. It challenges the status quo of watchmaking with bold product design and just like the timepieces themselves, Hublot wearers aren’t afraid to stand out. Two decades ago, the introduction of the Big Bang collection ignited a shift in the industry by daring to fuse unconventional materials and disregard traditional tropes of the category. Hublot and its Big Bang have gone from one showstopper to another, building on a spirit of revolution, audacity and playfulness. With many world-firsts and genre-defying feats, the Big Bang will go down in history as the first truly iconic watch of the 21st century and a beacon of creativity in a field that’s usually confined by history and tradition.

The campaign unveils Hublot’s new tagline – “Own It”. A bold and unapologetic call to action, and an uncompromising mindset. This new mantra captures the authentic, loud, and polarising spirit of the brand. Hublot has chosen the one and only Choupette, who doesn’t have a wrist or know how to tell the time. Choupette, a cultural icon, brings her signature attitude to a campaign that celebrates outrageous confidence and radical individuality that define both her and Hublot.

Julien Tornare, Hublot’s CEO says: “The Big Bang represents a revolution in watchmaking, a perfect union of tradition and modernity. While remaining rooted in the values of luxury watchmaking, such as artisanal quality and attention to detail, Hublot has managed to position the Big Bang as a disruptor within an industry that has traditionally seen little design innovation. This is what sets us apart.”

Captured by visionary photographer Carlijn Jacobs, the campaign unfolds in a series of striking, high fashion visuals interspersed with meme-inspired content. With this, Hublot embraces the new language of luxury on social media, engaging people with storytelling, playfulness and unpredictability. 

From ‘failed’ takes to Choupette’s diva moments, the campaign is far from another polished luxury marketing campaign. Including behind-the-scenes footage it offers a rare, self-aware glimpse into a luxury world that doesn’t take itself too seriously. Putting this low filter lens on high luxury allows Hublot to break the fourth wall and bring its audience into the moment, rather than observe from afar.

The campaign commenced on 1st May where Choupette is modelling the Big Bang 20th Anniversary Red Magic. Throughout the month, the spotlight shifts to two more icons: the striking Big Bang Tourbillon Automatic Yellow Neon Saxem, worn by a chic mysterious lady in a statement faux-fur coat, and the Big Bang 20th Anniversary Titanium Ceramic piece, seen on a powerful athlete unapologetically working out right in a gym locker.

Contact
v.pela@hublot.ch 

 

Hublot Big Bang 20th Anniversary Red Magic and Choupette
Hublot Big Bang 20th Anniversary Red Magic and Choupette

 

 

Benchling and Moderna Collaborate on AI-Driven Research

SAN FRANCISCO and BOSTON, May 7, 2025 /PRNewswire/ — Benchling, the R&D platform powering the biotech industry, today announced an expanded collaboration with Moderna. What began with Benchling supporting Moderna’s technical development teams — such as analytical development, technical operations, process development, and formulations — has grown into a broader rollout across the company’s research organization. The expansion will bring hundreds of Moderna’s scientists onto a unified, AI-ready research and development digital platform built to accelerate discovery and innovation.

“Moderna was built on the belief that technology and science together drive breakthroughs in medicine,” said Wade Davis, Senior Vice President, Digital at Moderna. “AI is creating extraordinary opportunities in science, but realizing its full potential requires entirely new ways of working. Benchling is tackling these industry-wide challenges head-on. Through this collaboration, our scientists have access to a strong foundation for AI and our computational scientists and engineers are empowered to do truly cutting-edge work.”

A new standard for digital transformation in biotech

Moderna and Benchling are focused on three priorities with this digital transformation: consolidating systems to create a seamless experience for scientists, automating scientific workflows, and standardizing data into consistent, AI-ready formats.

“R&D teams are under constant pressure to move faster and work more efficiently. AI and automation can unlock new levels of productivity, but only with the right infrastructure,” said Sajith Wickramasekara, CEO and co-founder of Benchling. “Moderna and Benchling are showing what the future of R&D looks like—fully digital, deeply integrated and built for intelligence and scale.”

Innovating the infrastructure for AI in biotech

Moderna’s research and technical development teams required a flexible system that could scale with their pipeline. Benchling’s digital platform addresses these needs by balancing agility with out-of-the box scientific workflows. Moderna’s digital teams use Benchling’s developer platform to build and deploy custom workflows, automate template generation, and integrate proprietary machine learning models. This shift reduces setup time for new workflows and enables high-throughput processing of experimental data—allowing digital teams to focus on innovation instead of maintaining systems. 

As Benchling rolls out across the research organization, scientists can design experiments, track samples, and analyze results within a single system, eliminating the friction of disconnected tools. The platform also addresses a long-standing industry challenge: integrating both structured and unstructured data across diverse research environments, laying the groundwork for AI-driven analysis across therapeutic areas.

Through this collaboration, the two companies are redefining how modern biotech research is done, setting a new standard for the digital infrastructure behind AI-driven R&D.

Dow and Pan Era Group advance their strategic partnership to increase the supply of high-quality PCR resins in Southeast Asia

With this new agreement, Dow will acquire its flexible polyethylene post-consumer recycled (PCR) resins from Pan Era Group.

JAKARTA, Indonesia, May 7, 2025 /PRNewswire/ — Dow (NYSE: DOW), a global leader in materials science, signed a second memorandum of understanding (MOU) with PT Eterna Persada Indonesia (PT Eterna), a leading Indonesian recycling company under the Pan Era Group. This agreement will strengthen the collaboration between the two companies to increase the supply of high-quality post-consumer recycled (PCR) resins and advance the plastics circular economy in Indonesia.

The new MOU builds on the successful partnership established in October 2022, which saw the launch of several new PCR resin grades for several applications, including collation shrink film (CSF).

Under the terms of this second agreement, Dow will develop a target volume of flexible polyethylene PCR resins from Pan Era Group over the next three years. These high-quality PCR resins are manufactured under stringent processes to meet Dow’s standards. They incorporate Dow’s advanced technology along with Pan Era Group’s decades of experience in this field, providing comprehensive solutions to end-customers. In addition, Dow and Pan Era Group will also explore the potential of developing new PCR resins for different applications, such as wire and cable jacketing, leveraging Dow’s materials science expertise and Pan Era Group’s local waste collection capabilities.

Meeting Indonesia’s drive towards a circular economy

“This MOU comes at a time when Indonesia’s recycling industry is undergoing a pivotal transformation, driven by increasing consumer awareness on environmental protection, supportive government regulations, and corporate sustainability initiatives,” says Wilson Pandhika, managing director of Pan Era Group. “The Indonesia government has been actively encouraging the development of a circular economy, which aims to optimize resource use, reduce waste, and create value from recycled materials. This collaboration between Pan Era Group and Dow not only aligns with these national goals and international targets but also demonstrates a shared commitment to fostering sustainable practices and driving a circular economy.”

“We are excited to strengthen our partnership with Pan Era Group. This agreement marks a significant milestone in our partnership and is a testament to Dow’s commitment to advancing circularity and meeting the growing demand for PCR in Indonesia and across Asia-Pacific,” says Bambang Candra, Asia-Pacific commercial vice president of Dow Packaging & Specialty Plastics. “By working together, we can create high-quality materials and advance recycling technologies to drive growth for the recycling industry in Indonesia. The increasing environmental awareness and government regulations in Indonesia present a unique opportunity for us to expand our portfolio of post-consumer recycled (PCR) resins.”

High resolution images available upon request.

About Dow Packaging and Specialty Plastics

Packaging and Specialty Plastics (P&SP), a business unit of Dow (NYSE: DOW), combines core strengths of R&D, worldwide reach, broad product lines and industry expertise to deliver high performing technologies for end use markets in food packaging, personal hygiene, infrastructure, consumer goods and transportation. P&SP is one of the world’s largest producers of polyethylene resins, functional polymers, and adhesives, and enabled by Pack Studios, is a leading innovator and collaborator across the value chain on sustainable application development and circular economy life-cycle design for plastics. www.dowpackaging.com.

About Dow

Dow (NYSE: DOW) is one of the world’s leading materials science companies, serving customers in high-growth markets such as packaging, infrastructure, mobility and consumer applications. Our global breadth, asset integration and scale, focused innovation, leading business positions and commitment to sustainability enable us to achieve profitable growth and help deliver a sustainable future. We operate manufacturing sites in 30 countries and employ approximately 36,000 people. Dow delivered sales of approximately $43 billion in 2024. References to Dow or the Company mean Dow Inc. and its subsidiaries. Learn more about us and our ambition to be the most innovative, customer-centric, inclusive and sustainable materials science company in the world by visiting www.dow.com.

About Pan Era Group

Pan Era Group is one of Southeast Asia’s leading and longest-established polyolefin recycling companies, known for pioneering sustainable plastic solutions. Through a comprehensive and integrated recycling process, the company maintains high operational standards while promoting the circular economy and reducing plastic waste’s environmental impact. By sourcing 100% of its input material from locally collected plastic waste in Indonesia, Pan Era Group helps to create social impact across the waste collection value chain. Its commitment to innovation and sustainability drives the delivery of high-quality recycled materials that help close the loop on plastic waste. To learn more, visit www.paneragroup.com.